{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:05:53Z","timestamp":1792404353982,"version":"4.4.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Rett syndrome (RTT) is rare neurodevelopmental disorder caused by mutations in the <jats:italic>MECP2<\/jats:italic> gene that encodes methyl-CpG-binding protein 2 (MeCP2), a DNA-binding protein with roles in epigenetic regulation of gene expression. Functional loss of MeCP2 results in abnormal neuronal maturation and plasticity, characterized by loss of verbal communication and loss of fine and gross motor function, among others. Trofinetide, a synthetic analog of glycine-proline-glutamate, was approved by the US Food and Drug Administration for the treatment of RTT in adult and pediatric patients aged 2\u00a0years and older. Here, we present the development of trofinetide from bench research to clinical studies and emphasize how the collaboration between academia, the pharmaceutical industry, and patient advocacy led to the recent approval. The bench-to-bedside development of trofinetide underscores the value of collaboration between these groups in the development and approval of treatments for rare diseases.<\/jats:p>","DOI":"10.3389\/fphar.2023.1341746","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T04:20:20Z","timestamp":1705897220000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Development of trofinetide for the treatment of Rett syndrome: from bench to bedside"],"prefix":"10.3389","volume":"14","author":[{"given":"Melissa","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Glaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Percy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Neul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Tropea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Horrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Nues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathie M.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"B1","volume-title":"DAYBUE (trofinetide) [package insert]","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat. Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fncel.2014.00018","article-title":"Developmental and maintenance defects in Rett syndrome neurons identified by a new mouse staging system in vitro","volume":"8","author":"Baj","year":"2014","journal-title":"Front. Cell Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ab.2003.08.032","article-title":"Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats","volume":"323","author":"Batchelor","year":"2003","journal-title":"Anal. Biochem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/cercor\/bhv078","article-title":"Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms","volume":"26","author":"Bedogni","year":"2016","journal-title":"Cereb. Cortex"},{"key":"B6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cne.22009","article-title":"Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks","volume":"514","author":"Belichenko","year":"2009","journal-title":"J. Comp. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","article-title":"NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke","volume":"278","author":"Bickerdike","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.bmc.2004.10.006","article-title":"Synthesis and pharmacological evaluation of side chain modified glutamic acid analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid (GPE)","volume":"13","author":"Brimble","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"B9","volume-title":"Open-label extension study of trofinetide for Rett syndrome","year":"2023"},{"key":"B10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10882-009-9168-2","article-title":"Communication in individuals with Rett syndrome: an assessment of forms and functions","volume":"22","author":"Didden","year":"2010","journal-title":"J. Dev. Phys. Disabil."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e000731","DOI":"10.1136\/bmjpo-2020-000731","article-title":"Multisystem comorbidities in classic Rett syndrome: a scoping review","volume":"4","author":"Fu","year":"","journal-title":"BMJ Paediatr. Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e000717","DOI":"10.1136\/bmjpo-2020-000717","article-title":"Consensus guidelines on managing Rett syndrome across the lifespan","volume":"4","author":"Fu","year":"","journal-title":"BMJ Paediatr. Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","article-title":"A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome","volume":"76","author":"Glaze","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"B15","first-page":"134","article-title":"Therapeutic use of insulin-like growth factor I: lessons from in vivo animal studies","volume":"383","author":"Gluckman","year":"1992","journal-title":"Acta Paediatr. Suppl."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1039\/b605293b","article-title":"Synthesis of macrocyclic analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid (GPE)","volume":"4","author":"Harris","year":"2006","journal-title":"Org. Biomol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.1016\/j.tet.2005.08.026","article-title":"Synthesis of proline-modified analogues of the neuroprotective agent glycyl-l-prolyl-glutamic acid (GPE)","volume":"61","author":"Harris","year":"2005","journal-title":"Tetrahedron"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1055\/s-0028-1088128","article-title":"Use of \u2018click chemistry\u2019 for the synthesis of tetrazole-containing analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid","volume":"8","author":"Hung","year":"2009","journal-title":"Synlett"},{"key":"B19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.bmc.2004.10.004","article-title":"Synthesis and pharmacological evaluation of glycine-modified analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid (GPE)","volume":"13","author":"Lai","year":"2005","journal-title":"Bioorg Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/jcbfm.2009.109","article-title":"NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats","volume":"29","author":"Lu","year":"2009","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678707.2023.2217328","article-title":"Recommendations for the management of diarrhea with trofinetide use in Rett syndrome","volume":"11","author":"Marsh","year":"2023","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12883-023-03181-y","article-title":"Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study","volume":"23","author":"May","year":"2023","journal-title":"BMC Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","article-title":"Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome","volume":"55","author":"Motil","year":"2012","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/1469-7610.00236","article-title":"The Rett syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome","volume":"43","author":"Mount","year":"2002","journal-title":"J. Child Psychol. Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1177\/0883073815579707","article-title":"Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression Scale","volume":"30","author":"Neul","year":"2015","journal-title":"J. Child Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/ana.22124","article-title":"Rett syndrome: revised diagnostic criteria and nomenclature","volume":"68","author":"Neul","year":"2010","journal-title":"Ann. Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"106704","DOI":"10.1016\/j.cct.2022.106704","article-title":"Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome","volume":"114","author":"Neul","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"B29","article-title":"Trofinetide for the treatment of Rett syndrome: results from the open-label extension LILAC study","author":"Percy","year":"2023"},{"key":"B30","article-title":"An open-label study of trofinetide for the treatment of Rett syndrome in girls 2\u20134 years of age (DAFFODIL)","author":"Percy","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/s0006-291x(89)80032-4","article-title":"Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide","volume":"165","author":"Sara","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1073\/pnas.0812394106","article-title":"Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice","volume":"106","author":"Tropea","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.bmc.2004.10.005","article-title":"Synthesis and neuroprotective activity of analogues of glycyl-L-prolyl-L-glutamic acid (GPE) modified at the alpha-carboxylic acid","volume":"13","author":"Trotter","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/17518423.2013.879940","article-title":"Parental perspectives on the communication abilities of their daughters with Rett syndrome","volume":"19","author":"Urbanowicz","year":"2016","journal-title":"Dev. Neurorehabil."},{"key":"B35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-2094-6-19","article-title":"NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats","volume":"6","author":"Wei","year":"2009","journal-title":"J. Neuroinflammation"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1341746\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T04:20:24Z","timestamp":1705897224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1341746\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":35,"alternative-id":["10.3389\/fphar.2023.1341746"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1341746","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"article-number":"1341746"}}